Here are the DEF 14A proxy statements from Rezolute, Inc. (RZLT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RZLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RZLT filings page.
Rezolute, Inc. (RZLT) scheduled its 2027 annual meeting for December 2, 2026, asking stockholders to elect seven directors and vote on four other proposals: auditor ratification, advisory executive compensation, a charter amendment to increase authorized common stock from 165,000,000 to 225,000,000 shares, and an adjournment if needed to solicit additional proxies when support for the share increase is insufficient. The share increase is subject to stockholder approval. Common stock outstanding and entitled to vote was 96,728,913 shares as of October 5, 2026.
Stockholders are also being asked to ratify Grant Thornton LLP as auditor for the fiscal year ending June 30, 2027. Audit fees were $603,220 for fiscal 2026 and $613,000 for fiscal 2025. The advisory vote on named executive compensation is non-binding. The 2026 summary compensation table lists total compensation of $5,711,410 for Chief Executive Officer Nevan Charles Elam, $2,564,957 for Chief Medical Officer Brian Roberts, $2,285,466 for Chief Financial and Business Officer Daron Evans, and $2,623,909 for Chief Commercial Officer Sunil Karnawat.